Jill Feldman, cofounder and president, EGFR Resisters, shares the importance of being proactive in managing dermatologic toxicities in epidermal growth factor receptor (EGFR)–positive lung cancer.
Jill Feldman
Advertisement
Lung cancer patient, advocate, cofounder and president of EGFR Resisters.
Articles by Jill Feldman
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
New PBM Laws Seek to Protect Independent Pharmacies but Could Raise Costs, Limit Patient Access
3
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
4
Measles Outbreaks Cause Financial, Public Health Burden in US
5
